Home > Publications Database > Prospective Multicenter Evaluation of the MDS 'Suggestive of PSP' Diagnostic Criteria. > print

001     277727
005     20250406001046.0
024 7 _ |a 10.1002/mds.30112
|2 doi
024 7 _ |a pmid:39797511
|2 pmid
024 7 _ |a pmc:PMC11926504
|2 pmc
024 7 _ |a 0885-3185
|2 ISSN
024 7 _ |a 1531-8257
|2 ISSN
024 7 _ |a altmetric:172933777
|2 altmetric
037 _ _ |a DZNE-2025-00448
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Quattrone, Andrea
|0 P:(DE-2719)9002627
|b 0
|u dzne
245 _ _ |a Prospective Multicenter Evaluation of the MDS 'Suggestive of PSP' Diagnostic Criteria.
260 _ _ |a New York, NY
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1743593399_11065
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The recent Movement Disorders Society (MDS)-progressive supranuclear palsy (PSP) diagnostic criteria conceptualized three clinical diagnostic certainty levels: 'suggestive of PSP' for sensitive early diagnosis based on subtle clinical signs, 'possible PSP' balancing sensitivity and specificity, and 'probable PSP' highly specific for PSP pathology.The aim of this study was to prospectively validate the criteria against long-term clinical follow-up and characterize the diagnostic certainty increase over time.Patients with 'possible PSP' or 'suggestive of PSP' diagnosis and clinical follow-up were recruited in two German multicenter longitudinal observational studies (ProPSP and DescribePSP). The cumulative percentage of patients longitudinally increasing diagnostic certainty was assessed over up to 2.5 years of follow-up. The sample size per arm required to detect 30% attenuated rate in diagnostic certainty increase in trials was estimated over multiple time intervals.Of 254 patients with available longitudinal data, 61 patients had low diagnostic certainty at baseline (48 suggestive of PSP, 13 possible PSP) and multiple clinical visits (median: 3, range: 2-4). The cumulative percentage of patients increasing diagnostic certainty progressed with follow-up duration (30.4% at 6 months, 51.7% at 1 year, 80.4% at 2.5 years). The sample size required to detect 30% reduction in diagnostic certainty increase rate within 1 year was 163, slightly smaller than that required using the PSP rating scale.Most 'suggestive of PSP' patients increased diagnostic certainty upon longitudinal follow-up, providing the first prospective multicenter validation of MDS-PSP diagnostic criteria. Our data support the design of trials tailored for these early-stage patients, suggesting the PSP rating scale and the diagnostic certainty increase rate as potential endpoint measures. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a diagnostic criteria
|2 Other
650 _ 7 |a longitudinal
|2 Other
650 _ 7 |a progressive supranuclear palsy
|2 Other
650 _ 7 |a suggestive of PSP
|2 Other
650 _ 7 |a validation
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: diagnosis
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Longitudinal Studies
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Sensitivity and Specificity
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
693 _ _ |0 EXP:(DE-2719)DESCRIBE-PSP-20160101
|5 EXP:(DE-2719)DESCRIBE-PSP-20160101
|e DZNE Clinical Registry Study of Neurodegenerative Diseases in Patients with Progressive Supranuclear Paresis (PSP)
|x 0
700 1 _ |a Franzmeier, Nicolai
|b 1
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 2
|u dzne
700 1 _ |a Petzold, Gabor C
|0 P:(DE-2719)2810273
|b 3
|u dzne
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 4
|u dzne
700 1 _ |a Brosseron, Frederic
|0 P:(DE-2719)2810593
|b 5
|u dzne
700 1 _ |a Falkenburger, Björn
|0 P:(DE-2719)2814178
|b 6
|u dzne
700 1 _ |a Prudlo, Johannes
|0 P:(DE-2719)2380559
|b 7
|u dzne
700 1 _ |a Gasser, Thomas
|0 P:(DE-2719)2320009
|b 8
|u dzne
700 1 _ |a DESCRIBE-PSP Group, The ProPSP Group
|b 9
|e Collaboration Author
700 1 _ |a Höglinger, Günter U
|0 P:(DE-2719)2811373
|b 10
|e Last author
|u dzne
700 1 _ |a Petzold, Gabor C
|0 P:(DE-2719)2810273
|b 11
|e Contributor
|u dzne
700 1 _ |a Kimmich, Okka
|0 P:(DE-2719)9002382
|b 12
|e Contributor
|u dzne
700 1 _ |a Falkenburger, Björn
|0 P:(DE-2719)2814178
|b 13
|e Contributor
|u dzne
700 1 _ |a Dinter, Elisabeth
|0 P:(DE-2719)9001016
|b 14
|e Contributor
|u dzne
700 1 _ |a Höglinger, Günter
|0 P:(DE-2719)2811373
|b 15
|e Contributor
|u dzne
700 1 _ |a Palleis, Carla
|0 P:(DE-2719)9000852
|b 16
|e Contributor
|u dzne
700 1 _ |a Bernhardt, Alexander Maximilian
|0 P:(DE-2719)9002620
|b 17
|e Contributor
|u dzne
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 18
|e Contributor
|u dzne
700 1 _ |a Katzdobler, Sabrina
|0 P:(DE-2719)9001160
|b 19
|e Contributor
|u dzne
700 1 _ |a Jäck, Alexander
|0 P:(DE-2719)9002626
|b 20
|e Contributor
|u dzne
700 1 _ |a Prudlo, Johannes
|0 P:(DE-2719)2380559
|b 21
|e Contributor
|u dzne
700 1 _ |a Gasser, Thomas
|0 P:(DE-2719)2320009
|b 22
|e Contributor
|u dzne
700 1 _ |a Brockmann, Kathrin
|0 P:(DE-2719)2811916
|b 23
|e Contributor
|u dzne
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 24
|e Contributor
|u dzne
700 1 _ |a Gamez, Anna
|0 P:(DE-2719)9001536
|b 25
|e Contributor
|u dzne
700 1 _ |a Brosseron, Frederic
|0 P:(DE-2719)2810593
|b 26
|e Contributor
|u dzne
700 1 _ |a Klietz, Martin
|b 27
|e Contributor
700 1 _ |a Wegner, Florian
|b 28
|e Contributor
700 1 _ |a Pötter-Nerger, Monika
|b 29
|e Contributor
700 1 _ |a Pedrosa, David J
|b 30
|e Contributor
700 1 _ |a Eggers, Carsten
|b 31
|e Contributor
700 1 _ |a Mollenhauer, Brit
|0 P:(DE-2719)9001340
|b 32
|e Contributor
|u dzne
700 1 _ |a Claus, Inga
|b 33
|e Contributor
700 1 _ |a Regensburger, Martin
|b 34
|e Contributor
700 1 _ |a Süß, Patrick
|b 35
|e Contributor
700 1 _ |a Warnecke, Tobias
|b 36
|e Contributor
700 1 _ |a Gandor, Florin
|b 37
|e Contributor
700 1 _ |a Gruber, Doreen
|b 38
|e Contributor
700 1 _ |a Berg, Daniela
|0 P:(DE-2719)2000059
|b 39
|e Contributor
700 1 _ |a Paschen, Steffen
|b 40
|e Contributor
700 1 _ |a Claßen, Joseph
|b 41
|e Contributor
700 1 _ |a Kassubek, Jan
|0 P:(DE-2719)9001967
|b 42
|e Contributor
|u dzne
700 1 _ |a Jost, Wolfgang H
|b 43
|e Contributor
700 1 _ |a Tönges, Lars
|b 44
|e Contributor
773 _ _ |a 10.1002/mds.30112
|g Vol. 40, no. 3, p. 526 - 536
|0 PERI:(DE-600)2041249-6
|n 3
|p 526 - 536
|t Movement disorders
|v 40
|y 2025
|x 0885-3185
856 4 _ |u https://pub.dzne.de/record/277727/files/DZNE-2025-00448%20SUP.zip
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/277727/files/DZNE-2025-00448.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/277727/files/DZNE-2025-00448.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:277727
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 0
|6 P:(DE-2719)9002627
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2811659
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2810273
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2811324
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2810593
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2814178
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2380559
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2320009
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2811373
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 11
|6 P:(DE-2719)2810273
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 12
|6 P:(DE-2719)9002382
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 13
|6 P:(DE-2719)2814178
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 14
|6 P:(DE-2719)9001016
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 15
|6 P:(DE-2719)2811373
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 16
|6 P:(DE-2719)9000852
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 17
|6 P:(DE-2719)9002620
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 18
|6 P:(DE-2719)2811659
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 19
|6 P:(DE-2719)9001160
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 20
|6 P:(DE-2719)9002626
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 21
|6 P:(DE-2719)2380559
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 22
|6 P:(DE-2719)2320009
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 23
|6 P:(DE-2719)2811916
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 24
|6 P:(DE-2719)2811324
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 25
|6 P:(DE-2719)9001536
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 26
|6 P:(DE-2719)2810593
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 32
|6 P:(DE-2719)9001340
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 42
|6 P:(DE-2719)9001967
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-16
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOVEMENT DISORD : 2022
|d 2024-12-16
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-16
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-16
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOVEMENT DISORD : 2022
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-16
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-16
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
920 1 _ |0 I:(DE-2719)1111016
|k AG Levin
|l Clinical Neurodegeneration
|x 1
920 1 _ |0 I:(DE-2719)1013020
|k AG Petzold
|l Vascular Neurology
|x 2
920 1 _ |0 I:(DE-2719)1011103
|k AG Spottke
|l Clinical Research Platform (CRP)
|x 3
920 1 _ |0 I:(DE-2719)1011303
|k AG Heneka
|l Neuroinflammation, Biomarker
|x 4
920 1 _ |0 I:(DE-2719)1710012
|k AG Falkenburger
|l Translational Parkinson Research
|x 5
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 6
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 7
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1111016
980 _ _ |a I:(DE-2719)1013020
980 _ _ |a I:(DE-2719)1011103
980 _ _ |a I:(DE-2719)1011303
980 _ _ |a I:(DE-2719)1710012
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)1210000
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21